Clinical Trial Update: Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating multiple oral doses of BI 207127 in treatment-naïve and treatment-experienced patients with chronic Hepatitis C. Results were posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BI 207127 (BI-207127)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C, Chronic | Phase 1 | Status: COMPLETED | Results posted: 2016-06-06